- Home
- COP vs GILD Comparison
COP vs GILD Comparison
Compare COP & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COP
- GILD
- Stock Information
- Founded
- COP 1917
- GILD 1987
- Country
- COP United States
- GILD United States
- Employees
- COP N/A
- GILD N/A
- Industry
- COP Integrated oil Companies
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COP Energy
- GILD Health Care
- Exchange
- COP Nasdaq
- GILD Nasdaq
- Market Cap
- COP 123.0B
- GILD 113.0B
- IPO Year
- COP N/A
- GILD 1992
- Fundamental
- Price
- COP $105.84
- GILD $91.84
- Analyst Decision
- COP Buy
- GILD Buy
- Analyst Count
- COP 17
- GILD 26
- Target Price
- COP $136.19
- GILD $98.17
- AVG Volume (30 Days)
- COP 7.2M
- GILD 6.6M
- Earning Date
- COP 02-06-2025
- GILD 02-11-2025
- Dividend Yield
- COP 2.95%
- GILD 3.35%
- EPS Growth
- COP N/A
- GILD N/A
- EPS
- COP 8.44
- GILD 0.10
- Revenue
- COP $56,924,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- COP N/A
- GILD $6.50
- Revenue Next Year
- COP $11.33
- GILD $0.36
- P/E Ratio
- COP $12.54
- GILD $908.39
- Revenue Growth
- COP N/A
- GILD 3.31
- 52 Week Low
- COP $94.23
- GILD $62.07
- 52 Week High
- COP $135.18
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- COP 65.50
- GILD 51.58
- Support Level
- COP $99.64
- GILD $90.82
- Resistance Level
- COP $106.17
- GILD $93.07
- Average True Range (ATR)
- COP 1.89
- GILD 1.54
- MACD
- COP 1.09
- GILD -0.03
- Stochastic Oscillator
- COP 96.71
- GILD 56.28
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).